Novo Nordisk
| Use attributes for filter ! | |
| Web site | www.novonordisk.com |
|---|---|
| Stock price | NOVO-B |
| Disclaimer | |
| Headquarters | Bagsværd |
| Denmark | |
| Ceo | Lars Fruergaard Jørgensen |
| Revenue | 111. 7 billion DKK (2017) |
| Founders | Hans Christian Hagedorn |
| Subsidiaries | Ziylo Ltd |
| Aldaph SpA | |
| Calibrium, LLC | |
| Did you know | Novo Nordisk is the world's 10th-largest independent biotech company by market cap ($111. 9 B). |
| Address | Etiler Mahallesi, Nispetiye Cd. Akmerkez İş Kuleleri E3 Blok, 34335 Beşiktaş/İstanbul |
| Phone | (0212) 385 40 40 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 713149 |
About Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.
Where is the Novo Nordisk
The online black market cashing in on weight loss jab hype
... Drugs manufacturer Novo Nordisk is the only company approved to sell and market semaglutide, branded as Ozempic and Wegovy, in the UK, but it is now battling against knock-off online sales...
Wegovy: Weight-loss drug firm becomes Europe's most valuable
... Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK...
NHS gets limited stock of Wegovy weight-loss jab
... The Danish maker of Wegovy, Novo Nordisk, said it would continue to restrict global supplies as it works to ramp up manufacturing...
Weight-loss apps to offer NHS help to obese
... The company which makes it, Novo Nordisk, recently said it was restricting the number of doses it is supplying to different countries to make sure patients have the correct all-round care and support in place when they start taking the drug...
Weight-loss drug reduces stroke and heart risk
... But the company behind the drug, Novo Nordisk, says it has a clear medical benefit, as well as being able to help people lose weight...
Weight-loss jabs investigated for suicide risk
... Manufacturer Novo Nordisk is working with the EMA and says patient safety is a top priority...
Weight loss drug semaglutide approved for NHS use
... Ozempic face Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor...
Hollywood weight loss jab to be sold by Boots chemist
... Boots will soon be offering an online service once the drug, made by Novo Nordisk, becomes available in the UK...
NHS gets limited stock of Wegovy weight-loss jab
By Michelle RobertsDigital health editor
Some NHS patients could be prescribed the Wegovy weight-loss drug after limited stock arrived in the UK.
The injection will be offered by some specialist NHS weight-loss management services, as well as some private clinics.
As doses become available, it could help tens of thousands of patients in England, the NHS said.
There has been a global shortage of the jabs, which blunt appetite. The cost to the health service is unclear.
What is Wegovy and does it work?Research suggests The Treatment , by making users feel they are already full so they eat less.
Experts warn the jabs - widely used in the US and endorsed by many celebrities - are not a quick fix nor a substitute for a healthy diet and exercise.
In trials, users often put weight back on after stopping treatment.
It is not clear how much stock the NHS will be able to access or what it will cost but the health service often negotiates a confidential discount with drug manufacturers. The List price for a pack of four pre-filled pens is £73. 25. Users inject themselves once a week.
Some high street pharmacies, as well as private medical providers, have said they plan to, offering a full prescribing and dispensing service.
The Danish maker of Wegovy, Novo Nordisk , said it would continue to restrict global supplies as it works to ramp up manufacturing.
It said in a statement there would be a controlled and limited launch: " As we expect supply to be constrained for the foreseeable future, a proportion of available supply will be allocated for use only within the NHS.
" We will continue to work with healthcare professionals to help ensure that patients with the highest unmet medical need are prioritised.
" We Are closely monitoring demand and are working with regulators and providers to ensure people living with obesity can have access to and remain on The Treatment . "
Say patients can only access Wegovy, which contains the drug semaglutide, if they are significantly overweight and have weight-related health problems.
Eligible patient can be prescribed it for a maximum of two years via specialist weight-management services, alongside diet and exercise advice.
These services are largely hospital based, meaning only about 35,000 have access, but the government says tens of thousands more people could be eligible if.
Related TopicsSource of news: bbc.com
